Session » (1554–1578) Vasculitis – Non-ANCA-Associated & Related Disorders Poster II
-
Abstract Number: 1554
Therapeutic Approaches and Predictive Factors of Relapse in Severe Ocular Involvement in Behçet’s Disease: A Multicentre Retrospective Study
-
Abstract Number: 1555
Axial Spondyloarthritis in Patients with Gastrointestinal Involvement of Behçet Syndrome
-
Abstract Number: 1556
Abdominal Surgical Interventions Among Patients with Gastrointestinal Involvement of Behçet Syndrome
-
Abstract Number: 1557
De Novo Manifestations During Adalimumab Treatment in Behçet Syndrome
-
Abstract Number: 1558
Development of Posterior Uveitis in Behçet’s Syndrome Patients with Vitreous Cells Without Any Other Posterior Involvement
-
Abstract Number: 1559
Comparison of Treatment with Adalimumab, Infliximab and Certolizumab in Refractory Cystoid Macular Edema Due to Behçet Disease
-
Abstract Number: 1560
Decreased Level of Peripheral CLA+ Treg Is a Protective Factor of Nervous System Involvement in Behcet’s Syndrome: A Real-World Study in China
-
Abstract Number: 1561
Clinical Features and Quality of Life of Japanese Bechet’s Disease Patients with Arthritis: A Japanese Monocentric Study
-
Abstract Number: 1562
Behcet’s Disease Coagulopathy in a Racially Diverse Patient Population
-
Abstract Number: 1563
Methotrexate: A Safe and Effective Therapeutic Alternative in Behçet´s Disease
-
Abstract Number: 1564
Common Femoral Vein Wall Thickness Measurement as a Diagnostic Test in Suspected Behçet’s Disease
-
Abstract Number: 1565
Baseline Vascular Ultrasound of Polymyalgia Rheumatica Patients at Time of Diagnosis Predicts Clinical Outcomes at 3 Months
-
Abstract Number: 1566
Exposure-Response Analysis of Sarilumab in Patients with Polymyalgia Rheumatica
-
Abstract Number: 1567
Assessment of the Extent and Accrual of Damage in Takayasu’s Arteritis
-
Abstract Number: 1568
Comparison of Methotrexate and Azathioprine as the First Steroid-Sparing Immunosuppressive Agent in Patients with Takayasu’s Arteritis
-
Abstract Number: 1569
Efficacy and Safety of Tofacitinib and Tocilizumab in 84 Patients with Takayasu Arteritis: Single-Center Post-Hoc Analysis of a Prospective Study
-
Abstract Number: 1570
Prognostic Assessment of the 2022 ACR/EULAR Classification Criteria for Takayasu Arteritis: A Multi-centre International Study
-
Abstract Number: 1571
Tocilizumab in Pregnant Takayasu Arteritis – The Use of Tocilizumab at Conception and Throughout Pregnancy in Those with Takayasu Arteritis
-
Abstract Number: 1572
Long-term Efficacy and Retention Rate of Molecular Targeted Drugs in Takayasu Arteritis
-
Abstract Number: 1573
Inpatient Prevalence and Comorbidity of Takayasu’s Arteritis: Nationwide Inpatient Sample 2016-2020
-
Abstract Number: 1574
The Role of 18F-FDG PET/CT Scans in Takayasu Arteritis
-
Abstract Number: 1575
Takayasu Arteritis Is Associated with Worse Fatigue Than Healthy Controls Which Persists over Time – A Longitudinal Cohort Study
-
Abstract Number: 1576
Application of the 2022 ACR/EULAR Criteria for Takayasu Arteritis to Previously Diagnosed Patients Based on the 1990 ACR Criteria
-
Abstract Number: 1577
Analysis of Takayasu’s Arteritis as Risk Factor for Acute Coronary Syndrome